Emmaus Life Sciences (OTCMKTS:EMMA) Announces Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) issued its earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $3.85 million during the quarter.

Emmaus Life Sciences Price Performance

Shares of OTCMKTS:EMMA remained flat at $0.02 during midday trading on Wednesday. The stock had a trading volume of 60,000 shares, compared to its average volume of 3,210. The business’s 50 day simple moving average is $0.01 and its 200-day simple moving average is $0.01. Emmaus Life Sciences has a 52 week low of $0.01 and a 52 week high of $0.03. The firm has a market cap of $1.05 million, a PE ratio of -0.13 and a beta of 9.85.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.